Modulation of hepatitis B virus cccDNA transcription
US10143720B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 10, 2017 |
| Grant date | Dec 4, 2018 |
| Priority date | — |
| Expiry date | Apr 10, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K5/126
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides small molecule inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which are useful as therapeutics in the management of chronic HBV. The compounds of the invention achieve epigenetic modification of the cccDNA, histone modification and histone deacetylase activity inhibition, thus modulating HBV cccDNA. The present invention further provides methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.